<!DOCTYPE html>
<html lang="en">
<head>
	<title>AML Extended Panel: Flowcytometry (FCM) + Bone Marrow (BM) Karyotyping + FISH for Five Markers + FLT3 Gene Mutation</title>
	<meta charset="utf-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0">
	<meta name="description" content="The Ovarian Marker Profile is a comprehensive blood test that measures several markers associated with ovarian cancer. This profile includes tests for CA125, CEA, CA72.4, HE4, and the ROMA Index.">
	<meta property="og:title" content="" />
	<meta property="og:description" content=""/>
	<meta property="og:url" content="https://www.sprintdiagnostics.in<?php echo $_SERVER['REQUEST_URI'];?>" />
 <meta property="og:image" content="https://www.sprintdiagnostics.in/images/logo.webp" />
	<meta property="og:image:width" content="180"/>
<meta property="og:image:height" content="60"/>	


	
	


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [{
    "@type": "Question",
    "name": "How often should I get this test done?",
    "acceptedAnswer": {
      "@type": "Answer",
      "text": "The frequency of this test depends on your individual risk factors and your doctor's recommendations. If you're being treated for ovarian cancer, your doctor may recommend regular testing to monitor your response to treatment."
    }
  },{
    "@type": "Question",
    "name": "Can this test diagnose ovarian cancer?",
    "acceptedAnswer": {
      "@type": "Answer",
      "text": "While this test can suggest the presence of ovarian cancer, a definitive diagnosis usually requires additional tests such as imaging studies and a biopsy. However, the Ovarian Marker Profile can provide valuable information to guide further testing and treatment decisions."
    }
  },{
    "@type": "Question",
    "name": "What does an elevated level of CEA indicate?",
    "acceptedAnswer": {
      "@type": "Answer",
      "text": "CEA is a protein that can be elevated in certain types of cancer, including ovarian cancer. However, it's not specific to ovarian cancer and can be elevated in other cancers and some benign conditions."
    }
  }]
}
</script>

<script type="application/ld+json">
        {
          "@context": "https://schema.org/", 
          "@type": "BreadcrumbList", 
          "itemListElement": [{
                "@type": "ListItem", 
                "position": 1, 
                "name": "Home",
                "item": "https://www.sprintdiagnostics.in/"  
          },{
                "@type": "ListItem", 
                "position": 2, 
                "name": "Tests",
                "item": "https://www.sprintdiagnostics.in/hyderabad/profile/"  
          },{
                "@type": "ListItem", 
                "position": 3, 
                "name": "Ovarian Marker Profile: CA125, CEA, CA72.4, HE4, ROMA Index",
                "item": "https://www.sprintdiagnostics.in/hyderabad/profile/ovarian-marker-profile"  
          }]
        }
        </script>




	
	

</head>

	<!-- Google Tag Manager (noscript) -->

<!-- End Google Tag Manager (noscript) -->

	<?php include '../../side-nav.php';?>
	<div class="page-content">
		<!--section-->
		<div class="section mt-0">
			<div class="breadcrumbs-wrap">
				<div class="container">
					<div class="breadcrumbs">
						<a href="https://sprintdiagnostics.in/">Home</a>
						<a href="https://www.sprintdiagnostics.in/hyderabad/profile/">Profile</a>
						<span>AML Extended Panel: Flowcytometry (FCM) + Bone Marrow (BM) Karyotyping + FISH for Five Markers + FLT3 Gene Mutation </span>
					</div>
				</div>
			</div>
		</div>
		<!--//section-->
		<!--section-->
		<div class="section page-content-first">
			<div class="container mt-6">
				<div class="row">
					<div class="col-md-8 col-lg-8 mt-0 mt-md-0 mb-4">
 					<h1 class="test-h1"> AML Extended Panel: Flowcytometry (FCM) + Bone Marrow (BM) Karyotyping + FISH for Five Markers + FLT3 Gene Mutation</h1>
					<div class="post-text">
								<p>Acute Myeloid Leukemia (AML) is a type of blood cancer that affects the bone marrow and impedes the production of normal blood cells. The AML Extended Panel is a comprehensive diagnostic test that combines flow cytometry, bone marrow karyotyping, Fluorescence In Situ Hybridization (FISH) for five markers, and testing for FLT3 gene mutation. This in-depth analysis provides valuable information about the cellular and genetic characteristics of AML, which is critical for diagnosis, risk stratification, and determining the most appropriate treatment strategy.</p>
								<p>Flow cytometry (FCM) is a technology used to analyze the physical and chemical properties of cells in a blood sample. Bone marrow karyotyping examines the chromosomes in the bone marrow cells for abnormalities. FISH helps detect specific DNA sequences and chromosomal changes, and FLT3 gene mutation analysis determines the presence of mutations in the FLT3 gene, which are common in AML.</p>
																	
								<div class="table-wrap">
									<table class="table table-striped">
							  <thead>
							    <tr>
							      <th scope="col">Test Name</th>
							      <td scope="col">AML Extended Panel: Flowcytometry (FCM) + Bone Marrow (BM) Karyotyping + FISH for Five Markers + FLT3 Gene Mutation </td>
							      
							    </tr>
							  </thead>
							  <tbody>
							    <tr>
							      <th scope="row">Sample Type</th>
							      <td>Bone Marrow / Blood</td>
							      
							    </tr>
							    <tr>
							      <th scope="row">Preparations Required</th>
							      <td>No fasting is required for this test. However, it is crucial to inform your doctor about any medications or supplements you are currently taking.</td>
							      
							    </tr>
							    <tr>
							      <th scope="row">Report Time</th>
							      <td>12 days</td>
							      
							    </tr>
								<tr>
							      <th scope="row">Price</th>
							      <td>₹ 10500</td>
							      
							    </tr>
							  </tbody>
							</table>
							
						</div>
					<div class="post-text">

<h2 class="test-h2 mt-3">What is the significance of the AML Extended Panel in managing AML?</h2>
<p>The AML Extended Panel is essential for diagnosing AML, determining the risk level of the disease, and guiding treatment decisions. It helps doctors understand the complex genetic makeup of AML and tailor a treatment plan according to the patient’s specific condition.</p>
<h2 class="test-h2 mt-3">What is flow cytometry and how does it help in AML diagnosis?</h2>
<p>Flow cytometry is a laboratory technique used to measure the physical and chemical characteristics of cells. In AML, flow cytometry is used to identify abnormal leukemia cells based on the presence of specific markers on their surface. This information is crucial for diagnosing AML and differentiating it from other types of leukemia.</p>
<h2 class="test-h2 mt-3">What is karyotyping and why is it significant?</h2>
<p>Karyotyping is the process of examining chromosomes in a sample of cells. In AML, karyotyping of bone marrow cells can reveal abnormalities in the number or structure of chromosomes, which can provide insights into the aggressiveness and prognosis of the disease.</p>
<h2 class="test-h2 mt-3">What is FISH and how is it used in AML?</h2>
<p>FISH (Fluorescence In Situ Hybridization) is a test that uses fluorescent probes to detect specific DNA sequences in chromosomes. It is used to identify chromosomal abnormalities and gene mutations that are common in AML. This information is valuable for risk stratification and treatment planning.</p>
<h2 class="test-h2 mt-3">What is the FLT3 gene mutation and why is it important in AML?</h2>
<p>FLT3 is a gene often found to be mutated in AML. The presence of FLT3 mutations is associated with a more aggressive form of AML and can affect treatment response. Knowing the FLT3 mutation status can guide treatment decisions.</p>
<h2 class="test-h2 mt-3">Do I need to fast before taking the AML Extended Panel?</h2>
<p>No, there is no need to fast before taking the AML Extended Panel.</p>
<h2 class="test-h2 mt-3">How is the sample for this test collected?</h2>
<p>The sample is usually collected from the blood or bone marrow. The bone marrow sample is typically collected through a bone marrow aspiration procedure.</p>
<h2 class="test-h2 mt-3">What does a normal result look like?</h2>
<p>Normal results would indicate the absence of the specific chromosomal abnormalities and gene mutations associated with AML. However, interpretation should be done by a doctor who will consider the patient's overall clinical picture.</p>
<h2 class="test-h2 mt-3">What should I do if my test results are abnormal?</h2>
<p>If your test results are abnormal, it is important to consult your doctor to discuss the next steps. Your doctor will interpret the results and may recommend additional testing or treatment options.</p>
<h2 class="test-h2 mt-3"> How often should this test be done?</h2>
<p>The frequency of this test depends on the clinical status of the patient. It is usually done at diagnosis, and may be repeated during treatment to monitor the disease.</p>
<h2 class="test-h2 mt-3"> Can the AML Extended Panel predict how the disease will progress?</h2>
<p>Yes, the AML Extended Panel can help predict disease progression. The genetic and cellular information provided can indicate how aggressive the leukemia is and how likely it is to respond to treatment.</p>
<h2 class="test-h2 mt-3"> What are the factors that can affect the levels in this test?</h2>
<p>Factors such as medication use, infections, and other underlying health conditions can affect the results of this test.</p>
<h2 class="test-h2 mt-3"> Which doctor should I consult if my AML Extended Panel results are abnormal?</h2>
<p>You should consult a hematologist or oncologist if your AML Extended Panel results are abnormal.</p>
<h2 class="test-h2 mt-3"> Is this test only for newly diagnosed patients?</h2>
<p>No, this test can also be used for patients undergoing treatment to monitor disease progression and treatment response.</p>
<h2 class="test-h2 mt-3"> Can this test be used to monitor the effectiveness of treatment?</h2>
<p>Yes, the AML Extended Panel can be used to monitor the effectiveness of treatment by tracking changes in cellular characteristics and genetic markers over time.</p>
<p>Acquiring a deeper understanding of the genetic and cellular makeup of AML through the AML Extended Panel plays a significant role in managing this condition effectively. The combination of flow cytometry, karyotyping, FISH, and FLT3 mutation analysis provides a comprehensive assessment that is indispensable in diagnosis, risk assessment, and making informed treatment decisions. It is important for patients to discuss the findings and implications of this test with their doctor to develop a personalized treatment plan adapted to the specific characteristics of their disease. Regular monitoring through the AML Extended Panel is also key in evaluating the effectiveness of treatment and making necessary modifications.</p>

 
							</div>		
						</div>			
							
							 
						
				</div>

		    <!--form section-->
				<?php include "../../include/bookslot.php" ?>
       <!--form section-->

			</div>
		</div>
		<!--//section-->
	</div>
	<?php include '../../footer.php';?>
</body>
</html>